A tactical playbook for acquiring, integrating, and scaling lower middle market cosmetic surgery centers into a high-margin, PE-exit-ready platform.
Find Cosmetic Surgery Center Platform TargetsThe U.S. cosmetic surgery market is highly fragmented, with thousands of independent centers generating $1M–$5M in revenue. Growing 6–8% annually, driven by aging demographics and social media demand, the sector offers compelling roll-up economics for disciplined acquirers willing to navigate CPOM regulations and key-man risk.
Independent cosmetic surgery centers trade at 3.5–6x EBITDA. A scaled multi-location platform with diversified procedure mix, shared back-office infrastructure, and reduced physician dependency commands 7–10x EBITDA at exit — creating significant multiple arbitrage for roll-up operators leveraging SBA and PE capital.
Minimum $2M EBITDA with 20%+ Margins
Platform must generate sufficient cash flow to fund add-on acquisitions and carry integration costs without relying solely on outside capital or seller financing arrangements.
Diversified Procedure Mix — Surgical and Non-Surgical
Target centers with revenue split across high-margin surgical cases and recurring non-surgical treatments like Botox and fillers, reducing single-procedure concentration risk.
AAAHC or JCAHO Accredited In-Office Surgical Suite
Accredited facilities create barriers to entry, signal regulatory compliance, and support the MSO structure needed for CPOM-compliant multi-state expansion.
Associate Physicians or NPs Generating Independent Revenue
Platform location must demonstrate revenue sustainability beyond the founding surgeon, with mid-level providers contributing at least 30% of total procedure volume.
Sub-$2M EBITDA Centers Within 50-Mile Radius
Geographically proximate tuck-ins allow shared marketing spend, cross-referral networks, and consolidated back-office overhead without complex multi-market integration challenges.
Seller Willing to Stay 12–24 Months for Patient Transition
Physician retention post-close is critical for surgical patient retention. Earnout structures tied to revenue retention incentivize meaningful handoff to platform surgeons.
Clean Malpractice History and No Pending Litigation
Undisclosed tail liability and active claims create unquantifiable exposure. Add-ons must have verified clean claims history and adequate tail coverage before closing.
EMR Infrastructure and Documented Patient Database
Targets using established EMR systems with segmented patient records enable faster integration, anonymized diligence, and HIPAA-compliant marketing to the existing patient base.
Build your Cosmetic Surgery Center roll-up
DealFlow OS surfaces off-market Cosmetic Surgery Center targets with seller signals — the foundation of every successful roll-up.
Centralized Marketing and Patient Acquisition
Consolidating SEO, paid social, before/after content, and reputation management across locations reduces per-patient acquisition cost and drives consistent new patient volume platform-wide.
Non-Surgical Revenue Expansion via Injectors and Aestheticians
Adding high-volume Botox, filler, and laser treatment capacity at each location creates recurring revenue streams that reduce reliance on low-frequency, high-ticket surgical cases.
Back-Office Consolidation and MSO Overhead Reduction
Centralizing billing, credentialing, HR, and vendor contracts through the MSO entity eliminates redundant administrative overhead and improves EBITDA margins by 3–5 percentage points.
Cross-Location Surgeon Utilization and Scheduling Optimization
Routing specialized surgical cases to highest-volume locations and deploying associate surgeons across sites improves OR utilization rates and reduces unfilled surgical suite capacity.
A 4–6 location cosmetic surgery platform generating $5M–$10M EBITDA with reduced key-man risk and diversified non-surgical revenue is positioned for sale to a PE-backed national aesthetic chain or strategic acquirer at 7–10x EBITDA. Typical hold period is 4–6 years with a structured MSO/PC exit compliant with CPOM regulations in all operating states.
Most states prohibit non-physicians from owning medical practices. Roll-ups use an MSO structure — a non-medical entity owns business assets while a physician-owned PC retains clinical operations — enabling compliant multi-state expansion.
Physician departure post-close is the primary risk. Structuring earnouts tied to revenue retention and securing 12–24 month transition agreements with selling surgeons significantly reduces post-acquisition patient attrition.
SBA 7(a) loans are available for individual acquisitions up to approximately $5M. PE-backed platforms typically use SBA for initial platform purchases, then transition to senior debt facilities for subsequent add-on acquisitions.
Well-structured platforms with $5M+ EBITDA, reduced key-man dependency, and diversified procedure revenue typically trade at 7–10x EBITDA to strategic or PE buyers, versus 3.5–6x for standalone practices.
More Cosmetic Surgery Center Guides
DealFlow OS surfaces off-market platform targets with seller motivation scores. Free to join.
Find platform targets — freeNo credit card required
For Buyers
For Sellers